Abvc Biopharma Inc (ABVC)

$1.07 -0.07 (-6.14%)
Market Cap 29.00M
Revenue (ttm) 0.00
Net Income (ttm) -7.91M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 114,100
Avg Vol 91,916
Day's Range N/A - N/A
Shares Out 25.44M
Stochastic %K 0%
Beta 0.38
Analysts Strong Buy
Price Target $20.20

Company Profile

ABVC BioPharma, Inc., a clinical-stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials as a combination therapy for triple negative breast cancer; ABV-1504, which has completed Phase II clinical trials for depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1702, which is in Phase II cl...

Industry: Biotechnology
Sector: Healthcare
Phone: 510 668 0881
Address:
44370 Old Warm Springs Boulevard, Fremont, United States
topstockalerts
topstockalerts Apr. 24 at 9:58 PM
After Hours Top Gainers PT2 $HKPD $TANH $GOAI $ABVC $AIHS
0 · Reply
specctham
specctham Apr. 10 at 7:45 PM
$ABVC Someone is buying, alot. This can explode anytime.
0 · Reply
Swift_Trades
Swift_Trades Apr. 7 at 1:52 PM
$ABVC ✊👌🏼👌🏼
0 · Reply
specctham
specctham Apr. 6 at 8:55 PM
$ABVC Hmmm. Last time i bought at 0.7 and sold at 4. Watching closely here again.
0 · Reply
BigdollarMaker
BigdollarMaker Apr. 6 at 6:43 PM
$ABVC Could we get great news soon?
1 · Reply
prismmarketview
prismmarketview Apr. 6 at 4:22 PM
PRISM Mid-Day Movers: New Energy and Weight Loss are Today’s Leaders. Shares of Maxeon Solar Technologies, Ltd. (NASDAQ: $MAXN) are surging, up about 54%, as traders revisit the beaten‑down solar name on renewed financing and turnaround speculation, fueling a classic high‑beta relief rally from deeply oversold levels. Shares of Soleno Therapeutics, Inc. (NASDAQ: $SLNO) are trading sharply higher, up about 32%, as investors continue to bid up this late‑stage Prader‑Willi syndrome play, where even small shifts in sentiment or regulatory expectations can spark outsized moves. Other Notable Movers: Fubo TV ( $FUBO) up 28% ABVC BioPharma ( $ABVC) up 21% Biodexa Pharmaceuticals ( $BDRX) down -23% https://prismmarketview.com/prism-mid-day-movers-new-energy-and-weight-loss-are-todays-leaders/
0 · Reply
rombrento
rombrento Apr. 6 at 2:25 PM
$ABVC
0 · Reply
PaulLaurent
PaulLaurent Mar. 31 at 8:13 AM
a fast one - thank you! $HKIT $BIRD $PROP $DWSN $ABVC
0 · Reply
PaulLaurent
PaulLaurent Mar. 31 at 5:44 AM
🚀📈 Top Gainers 📈🚀AH $HKIT $BIRD $PROP $DWSN $ABVC
0 · Reply
topstockalerts
topstockalerts Mar. 30 at 11:59 PM
After Hours Top Gainers PT2 $HSDT $AFBI $BFRG $PROP $ABVC
0 · Reply
Latest News on ABVC
ABVC BioPharma Secures $200,000 in First Cash Licensing Payment From Oncology Products Partner, Totaling $546,000 From Three Partners

Dec 11, 2024, 6:30 AM EST - 1 year ago

ABVC BioPharma Secures $200,000 in First Cash Licensing Payment From Oncology Products Partner, Totaling $546,000 From Three Partners

ABVC BioPharma Receives $50,000 in Incremental Licensing Fees, Boosting Total Payments to $346,000 From Its Three Strategic Partners

Oct 22, 2024, 8:45 AM EDT - 1 year ago

ABVC BioPharma Receives $50,000 in Incremental Licensing Fees, Boosting Total Payments to $346,000 From Its Three Strategic Partners

ABVC BioPharma, Inc. Reports Strong Q2 2024 Financial Results and Strategic Achievements

Aug 15, 2024, 7:30 AM EDT - 1 year ago

ABVC BioPharma, Inc. Reports Strong Q2 2024 Financial Results and Strategic Achievements

AiBtl BioPharma Inc. Acquired TT Life Company, Valued at $8.33M, With 1.66M AiBtl Shares at $5 per Share

Apr 18, 2024, 9:25 AM EDT - 2 years ago

AiBtl BioPharma Inc. Acquired TT Life Company, Valued at $8.33M, With 1.66M AiBtl Shares at $5 per Share

ABVC BioPharma Executes a Global Licensing Definitive Agreement for the Treatment of NSCLC, Expecting Aggregate Income of $13.75M and Royalties of up to $12.50M

Apr 17, 2024, 9:00 AM EDT - 2 years ago

ABVC BioPharma Executes a Global Licensing Definitive Agreement for the Treatment of NSCLC, Expecting Aggregate Income of $13.75M and Royalties of up to $12.50M

ABVC BioPharma Executes a Global Licensing Term Sheet for Oncology/Hematology Products, Expecting Licensing Income of $55M and Royalties of up to $50M

Apr 10, 2024, 8:30 AM EDT - 2 years ago

ABVC BioPharma Executes a Global Licensing Term Sheet for Oncology/Hematology Products, Expecting Licensing Income of $55M and Royalties of up to $50M

ABVC BioPharma Entered into a Global Licensing Deal of Vitargus with Licensing Income of $33.5M and Royalties up to $60M

Mar 26, 2024, 8:30 AM EDT - 2 years ago

ABVC BioPharma Entered into a Global Licensing Deal of Vitargus with Licensing Income of $33.5M and Royalties up to $60M

ABVC BioPharma, Inc. CEO Selected as 2024 Top 10 CEO in CEO Insights Asia Magazine

Mar 19, 2024, 8:30 AM EDT - 2 years ago

ABVC BioPharma, Inc. CEO Selected as 2024 Top 10 CEO in CEO Insights Asia Magazine

ABVC BioPharma Reports Annual 2023 Financials and Provides Fiscal Year 2024 First Quarter Business Update

Mar 14, 2024, 9:30 AM EDT - 2 years ago

ABVC BioPharma Reports Annual 2023 Financials and Provides Fiscal Year 2024 First Quarter Business Update

ABVC BioPharma Executes a Definitive Agreement to Receive License Fees of $3M and Royalties of 2% on Future Revenues

Feb 15, 2024, 8:30 AM EST - 2 years ago

ABVC BioPharma Executes a Definitive Agreement to Receive License Fees of $3M and Royalties of 2% on Future Revenues

ABVC BioPharma Receives Australian Patent, Valid Until 2040, for Its Treatment of Major Depressive Disorder (MDD)

Feb 12, 2024, 8:30 AM EST - 2 years ago

ABVC BioPharma Receives Australian Patent, Valid Until 2040, for Its Treatment of Major Depressive Disorder (MDD)

ABVC Acquires $2.96 Million Worth of Land in Asia with Stocks Priced at $3.50 per Share

Feb 8, 2024, 9:17 AM EST - 2 years ago

ABVC Acquires $2.96 Million Worth of Land in Asia with Stocks Priced at $3.50 per Share

ABVC BioPharma and its Subsidiary Receive $460M From AiBtl BioPharma as the First Milestone Payment of Global Licensing Fees

Jan 3, 2024, 7:24 AM EST - 2 years ago

ABVC BioPharma and its Subsidiary Receive $460M From AiBtl BioPharma as the First Milestone Payment of Global Licensing Fees

ABVC BioPharma Announces Completion of Subject Treatment for Interim Analysis on ADHD Phase IIb Clinical Study

Dec 7, 2023, 8:30 AM EST - 2 years ago

ABVC BioPharma Announces Completion of Subject Treatment for Interim Analysis on ADHD Phase IIb Clinical Study

ABVC BioPharma Receives U.S. Patent for ADHD Treatment, a $32 Billion Market

Nov 21, 2023, 8:30 AM EST - 2 years ago

ABVC BioPharma Receives U.S. Patent for ADHD Treatment, a $32 Billion Market

ABVC BioPharma Enters Definitive Agreement with Licensing Income Worth $467M and Royalties Up to $200M

Nov 16, 2023, 10:05 AM EST - 2 years ago

ABVC BioPharma Enters Definitive Agreement with Licensing Income Worth $467M and Royalties Up to $200M

ABVC BioPharma Reports Third Quarter 2023 Financial and Operational Results

Nov 15, 2023, 9:00 AM EST - 2 years ago

ABVC BioPharma Reports Third Quarter 2023 Financial and Operational Results

ABVC BioPharma Entered Into a Term Sheet to License Global Rights of CNS Drugs with the Indications of MDD and ADHD to AiBtl BioPharma at the Valuation of $667 Million

Oct 26, 2023, 8:30 AM EDT - 2 years ago

ABVC BioPharma Entered Into a Term Sheet to License Global Rights of CNS Drugs with the Indications of MDD and ADHD to AiBtl BioPharma at the Valuation of $667 Million

ABVC BioPharma Announces Completion of Subject Recruitment for Interim Analysis on ADHD Phase IIb Clinical Study

Oct 17, 2023, 8:30 AM EDT - 2 years ago

ABVC BioPharma Announces Completion of Subject Recruitment for Interim Analysis on ADHD Phase IIb Clinical Study

ABVC BioPharma Receives Taiwanese Patent for Its Treatment of Major Depressive Disorder (MDD)

Oct 9, 2023, 8:30 AM EDT - 2 years ago

ABVC BioPharma Receives Taiwanese Patent for Its Treatment of Major Depressive Disorder (MDD)

ABVC BioPharma Provides Updates on ADHD Phase IIb Clinical Study

Aug 23, 2023, 8:30 AM EDT - 2 years ago

ABVC BioPharma Provides Updates on ADHD Phase IIb Clinical Study

ABVC Executes Cooperation Agreement for Strategic Investments

Aug 17, 2023, 9:19 AM EDT - 2 years ago

ABVC Executes Cooperation Agreement for Strategic Investments

ABVC BioPharma Regains Compliance With Nasdaq's Minimum Bid Price Requirement

Aug 10, 2023, 8:30 AM EDT - 2 years ago

ABVC BioPharma Regains Compliance With Nasdaq's Minimum Bid Price Requirement

ABVC Corporate Update and CEO's Letter to Shareholders

Aug 7, 2023, 8:30 AM EDT - 2 years ago

ABVC Corporate Update and CEO's Letter to Shareholders

ABVC Announces the Approval of the Plan for GMP Production Facilities of Vitargus by Taiwan Science Park Administration

Aug 3, 2023, 9:20 AM EDT - 2 years ago

ABVC Announces the Approval of the Plan for GMP Production Facilities of Vitargus by Taiwan Science Park Administration

ABVC Signs a Term Sheet to Earn Licensing Fees of up to $20M and Royalties of 5-12% of Net Sales

Aug 1, 2023, 8:30 AM EDT - 2 years ago

ABVC Signs a Term Sheet to Earn Licensing Fees of up to $20M and Royalties of 5-12% of Net Sales

ABVC BioPharma Announces Closing on $1.75 Million Registered Direct Offering

Jul 31, 2023, 9:30 AM EDT - 2 years ago

ABVC BioPharma Announces Closing on $1.75 Million Registered Direct Offering

ABVC BioPharma Announces Pricing of $1.75 Million Registered Direct Offering

Jul 27, 2023, 9:22 AM EDT - 2 years ago

ABVC BioPharma Announces Pricing of $1.75 Million Registered Direct Offering

ABVC Signs Term Sheet to Acquire Real Estate Assets for Strategic Investments

Jul 26, 2023, 8:30 AM EDT - 2 years ago

ABVC Signs Term Sheet to Acquire Real Estate Assets for Strategic Investments

ABVC BioPharma Announces Reverse Stock Split

Jul 24, 2023, 12:30 PM EDT - 2 years ago

ABVC BioPharma Announces Reverse Stock Split

The New CEO of ABVC BioPharma Takes Steps to Help Improve Cash Efficiency

Jul 6, 2023, 8:30 AM EDT - 3 years ago

The New CEO of ABVC BioPharma Takes Steps to Help Improve Cash Efficiency

ABVC BioPharma, Inc. Announces New CEO as It Targets Further Growth

Jun 26, 2023, 8:30 AM EDT - 3 years ago

ABVC BioPharma, Inc. Announces New CEO as It Targets Further Growth

ABVC BioPharma Subsidiary BioKey Projects $1.0 Million Proceeds From Dietary Supplement Production

Jun 20, 2023, 8:30 AM EDT - 3 years ago

ABVC BioPharma Subsidiary BioKey Projects $1.0 Million Proceeds From Dietary Supplement Production

ABVC BioPharma ADHD Phase II Part 2 Clinical Study First Subject Enrolled at UCSF

Jun 12, 2023, 8:30 AM EDT - 3 years ago

ABVC BioPharma ADHD Phase II Part 2 Clinical Study First Subject Enrolled at UCSF

ABVC BioPharma Announces Collaboration With MerDury BioPharma for New Product Development and Commercialization

Jun 6, 2023, 8:30 AM EDT - 3 years ago

ABVC BioPharma Announces Collaboration With MerDury BioPharma for New Product Development and Commercialization

ABVC BioPharma Vitargus® Phase II Study Received Ethical Approval at Sydney Eye Hospital in Australia

May 22, 2023, 8:30 AM EDT - 3 years ago

ABVC BioPharma Vitargus® Phase II Study Received Ethical Approval at Sydney Eye Hospital in Australia

ABVC BioPharma Provides ABV-1601 Update on Phase I Site Initiation Visit Conducted at Cedars-Sinai Medical Center (CSMC)

Apr 10, 2023, 8:30 AM EDT - 3 years ago

ABVC BioPharma Provides ABV-1601 Update on Phase I Site Initiation Visit Conducted at Cedars-Sinai Medical Center (CSMC)

ABVC BioPharma Provides Vitargus Update on Phase II Site Initiation Visit Conducted at Ramathibodi Hospital in Thailand

Apr 6, 2023, 8:30 AM EDT - 3 years ago

ABVC BioPharma Provides Vitargus Update on Phase II Site Initiation Visit Conducted at Ramathibodi Hospital in Thailand

ABVC BioPharma Announces Fiscal Year 2022 Financial and Operational Results

Mar 31, 2023, 6:49 PM EDT - 3 years ago

ABVC BioPharma Announces Fiscal Year 2022 Financial and Operational Results

ABVC BioPharma Provides Vitargus® Update on Phase II Site Initiation Visit Conducted at Srinagarind Hospital in Thailand

Mar 20, 2023, 7:00 AM EDT - 3 years ago

ABVC BioPharma Provides Vitargus® Update on Phase II Site Initiation Visit Conducted at Srinagarind Hospital in Thailand

ABVC BioPharma Receives Registration Approval for Maitake Mushroom Dietary Supplement by the Taiwan Ministry of Health and Welfare

Mar 14, 2023, 7:00 AM EDT - 3 years ago

ABVC BioPharma Receives Registration Approval for Maitake Mushroom Dietary Supplement by the Taiwan Ministry of Health and Welfare

ABVC BioPharma Provides 2023 Pipeline Update

Feb 28, 2023, 8:30 AM EST - 3 years ago

ABVC BioPharma Provides 2023 Pipeline Update

ABVC BioPharma Receives $3.175 Million Investment From The Lind Partners to Continue Clinical Trials

Feb 23, 2023, 4:16 PM EST - 3 years ago

ABVC BioPharma Receives $3.175 Million Investment From The Lind Partners to Continue Clinical Trials

ABVC BioPharma Receives Australian TGA Approval to Initiate Phase II Study of Vitargus®

Feb 21, 2023, 8:30 AM EST - 3 years ago

ABVC BioPharma Receives Australian TGA Approval to Initiate Phase II Study of Vitargus®

ABVC BioPharma ABV-1505 ADHD Phase IIa Results Presented at 2023 APSARD Conference

Jan 19, 2023, 8:30 AM EST - 3 years ago

ABVC BioPharma ABV-1505 ADHD Phase IIa Results Presented at 2023 APSARD Conference

FDA Approves IND Submission Allowing ABVC BioPharma to Proceed With Clinical Study of ABV-1519 for Treatment of Non-Small Cell Lung Cancer

Jan 5, 2023, 8:30 AM EST - 3 years ago

FDA Approves IND Submission Allowing ABVC BioPharma to Proceed With Clinical Study of ABV-1519 for Treatment of Non-Small Cell Lung Cancer

ABVC BioPharma Provides Vitargus® Update - Phase II Vitargus® Study Protocol Received Thai FDA Approval

Nov 17, 2022, 8:30 AM EST - 3 years ago

ABVC BioPharma Provides Vitargus® Update - Phase II Vitargus® Study Protocol Received Thai FDA Approval

ABVC BioPharma Reports Third Quarter 2022 Financial and Operational Results

Nov 14, 2022, 6:20 PM EST - 3 years ago

ABVC BioPharma Reports Third Quarter 2022 Financial and Operational Results

ABVC BioPharma Receives Notice of Allowance from US Patent and Trademark Office for ABV-1504 Used to Treat Major Depressive Disorder (MDD)

Nov 7, 2022, 8:30 AM EST - 3 years ago

ABVC BioPharma Receives Notice of Allowance from US Patent and Trademark Office for ABV-1504 Used to Treat Major Depressive Disorder (MDD)

Cedars-Sinai Medical Center Joins Phase I Clinical Study of ABVC BioPharma's Medication for Treating Depression in Cancer Patients

Nov 2, 2022, 8:30 AM EDT - 3 years ago

Cedars-Sinai Medical Center Joins Phase I Clinical Study of ABVC BioPharma's Medication for Treating Depression in Cancer Patients

topstockalerts
topstockalerts Apr. 24 at 9:58 PM
After Hours Top Gainers PT2 $HKPD $TANH $GOAI $ABVC $AIHS
0 · Reply
specctham
specctham Apr. 10 at 7:45 PM
$ABVC Someone is buying, alot. This can explode anytime.
0 · Reply
Swift_Trades
Swift_Trades Apr. 7 at 1:52 PM
$ABVC ✊👌🏼👌🏼
0 · Reply
specctham
specctham Apr. 6 at 8:55 PM
$ABVC Hmmm. Last time i bought at 0.7 and sold at 4. Watching closely here again.
0 · Reply
BigdollarMaker
BigdollarMaker Apr. 6 at 6:43 PM
$ABVC Could we get great news soon?
1 · Reply
prismmarketview
prismmarketview Apr. 6 at 4:22 PM
PRISM Mid-Day Movers: New Energy and Weight Loss are Today’s Leaders. Shares of Maxeon Solar Technologies, Ltd. (NASDAQ: $MAXN) are surging, up about 54%, as traders revisit the beaten‑down solar name on renewed financing and turnaround speculation, fueling a classic high‑beta relief rally from deeply oversold levels. Shares of Soleno Therapeutics, Inc. (NASDAQ: $SLNO) are trading sharply higher, up about 32%, as investors continue to bid up this late‑stage Prader‑Willi syndrome play, where even small shifts in sentiment or regulatory expectations can spark outsized moves. Other Notable Movers: Fubo TV ( $FUBO) up 28% ABVC BioPharma ( $ABVC) up 21% Biodexa Pharmaceuticals ( $BDRX) down -23% https://prismmarketview.com/prism-mid-day-movers-new-energy-and-weight-loss-are-todays-leaders/
0 · Reply
rombrento
rombrento Apr. 6 at 2:25 PM
$ABVC
0 · Reply
PaulLaurent
PaulLaurent Mar. 31 at 8:13 AM
a fast one - thank you! $HKIT $BIRD $PROP $DWSN $ABVC
0 · Reply
PaulLaurent
PaulLaurent Mar. 31 at 5:44 AM
🚀📈 Top Gainers 📈🚀AH $HKIT $BIRD $PROP $DWSN $ABVC
0 · Reply
topstockalerts
topstockalerts Mar. 30 at 11:59 PM
After Hours Top Gainers PT2 $HSDT $AFBI $BFRG $PROP $ABVC
0 · Reply
BigdollarMaker
BigdollarMaker Mar. 30 at 4:37 PM
$ABVC WTH is going on?
0 · Reply
KOWALSK1
KOWALSK1 Mar. 24 at 5:59 PM
Will tray $ABVC With tight stop Pt 1.80 1.90
0 · Reply
BigdollarMaker
BigdollarMaker Mar. 19 at 6:51 PM
$ABVC Lets go, we are
0 · Reply
BigdollarMaker
BigdollarMaker Mar. 9 at 5:56 PM
$ABVC
0 · Reply
ProfitGainer
ProfitGainer Mar. 4 at 5:46 PM
$ABVC https://finance.yahoo.com/news/abvc-biopharma-reports-2025-form-220000044.html
0 · Reply
BillionerOfKing
BillionerOfKing Mar. 4 at 12:16 AM
$ABVC Current Stock Price: $1.41 Contracts to trade: $2.5 ABVC Mar 20 2026 Call Entry: $0.58 Exit: $1.08 ROI: 88% Hold ~20 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
d_risk
d_risk Mar. 3 at 9:45 PM
$ABVC - ABVC BIOPHARMA, INC. - 10K - Updated Risk Factors ABVC’s 10-K risk section swelled with granular new warnings on drug-development dependence, side effects, product liability without general insurance, FDA and cGMP hurdles, foreign trial data acceptance, third‑party and licensing failures (BioHopeKing, Yukiguni), international and Taiwan geopolitical/exchange risks, penny stock and Nasdaq delisting exposure, concentrated licensee revenues, and detailed dilution/financing pressures, while paring back trade secret, anti-corruption, analyst, and some stock-volatility boilerplate. #Biopharmaceuticals #DrugDevelopmentRisks #RegulatoryCompliance #GeopoliticalRisk #FinancialDilution 🟢 Added 🟠 Removed https://d-risk.ai/ABVC/10-K/2026-03-03
0 · Reply
BigdollarMaker
BigdollarMaker Feb. 24 at 7:12 PM
$ABVC
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 19 at 5:17 PM
$ABVC RSI: 20.69, MACD: -0.1463 Vol: 0.19, MA20: 1.84, MA50: 2.04 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
ChristinePeacock469
ChristinePeacock469 Feb. 18 at 12:43 PM
$ABVC Psychedelic biotech where regulatory pathways dominate sentiment.
0 · Reply
QuietTrader25
QuietTrader25 Feb. 17 at 8:13 PM
$ABVC No sales yet, burning cash, tiny ~$41M market cap, trading ~$1.63-1.67 lately (down from $5+ highs last year). Volatile microcap risks: dilution from equity plans, trial delays, funding needs. But if any candidate hits (botanical angle could differentiate), big upside. High-risk lottery ticket. You dipping in or just scouting?
0 · Reply